Article

Recommended tests for association in 2 x 2 tables.

Unit for Applied Clinical Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Statistics in Medicine (Impact Factor: 2.04). 03/2009; 28(7):1159-75. DOI: 10.1002/sim.3531
Source: PubMed

ABSTRACT The asymptotic Pearson's chi-squared test and Fisher's exact test have long been the most used for testing association in 2x2 tables. Unconditional tests preserve the significance level and generally are more powerful than Fisher's exact test for moderate to small samples, but previously were disadvantaged by being computationally demanding. This disadvantage is now moot, as software to facilitate unconditional tests has been available for years. Moreover, Fisher's exact test with mid-p adjustment gives about the same results as an unconditional test. Consequently, several better tests are available, and the choice of a test should depend only on its merits for the application involved. Unconditional tests and the mid-p approach ought to be used more than they now are. The traditional Fisher's exact test should practically never be used.

2 Followers
 · 
313 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: PLINK 1 is a widely used open-source C/C++ toolset for genome-wide association studies (GWAS) and research in population genetics. However, the steady accumulation of data from imputation and whole-genome sequencing studies has exposed a strong need for faster and scalable implementations of key functions, such as logistic regression, linkage disequilibrium estimation, and genomic distance evaluation. In addition, GWAS and population-genetic data now frequently contain genotype likelihoods, phase information, and/or multiallelic variants, none of which can be represented by PLINK 1's primary data format. To address these issues, we are developing a second-generation codebase for PLINK. The first major release from this codebase, PLINK 1.9, introduces extensive use of bit-level parallelism, [Formula: see text]-time/constant-space Hardy-Weinberg equilibrium and Fisher's exact tests, and many other algorithmic improvements. In combination, these changes accelerate most operations by 1-4 orders of magnitude, and allow the program to handle datasets too large to fit in RAM. We have also developed an extension to the data format which adds low-overhead support for genotype likelihoods, phase, multiallelic variants, and reference vs. alternate alleles, which is the basis of our planned second release (PLINK 2.0). The second-generation versions of PLINK will offer dramatic improvements in performance and compatibility. For the first time, users without access to high-end computing resources can perform several essential analyses of the feature-rich and very large genetic datasets coming into use.
    10/2014; 4(1). DOI:10.1186/s13742-015-0047-8
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper proposes a general exact meta-analysis approach for synthesizing inferences from multiple studies of discrete data. The approach combines the p-value functions (also known as significance functions) associated with the exact tests from individual studies. It encompasses a broad class of exact meta-analysis methods, as it permits broad choices for the combining elements, such as tests used in individual studies, and any parameter of interest. The approach yields statements that explicitly account for the impact of individual studies on the overall inference, in terms of efficiency/power and the type I error rate. Those statements also give rises to empirical methods for further enhancing the combined inference. Although the proposed approach is for general discrete settings, for convenience, it is illustrated throughout using the setting of meta-analysis of multiple 2 × 2 tables. In the context of rare events data, such as observing few, zero or zero total (i.e., zero events in both arms) outcomes in binomial trials or 2 × 2 tables, most existing meta-analysis methods rely on the large-sample approximations which may yield invalid inference. The commonly used corrections to zero outcomes in rare events data, aiming to improve numerical performance can also incur undesirable consequences. The proposed approach applies readily to any rare event setting, including even the zero total event studies without any artificial correction. While debates continue on whether or how zero total event studies should be incorporated in meta-analysis, the proposed approach has the advantage of automatically including those studies and thus making use of all available data. Through numerical studies in rare events settings, the proposed exact approach is shown to be efficient and, generally, outperform commonly used meta-analysis methods, including Mental-Haenszel and Peto methods.
    Journal of the American Statistical Association 10/2014; 109(508). DOI:10.1080/01621459.2014.946318 · 2.11 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Direct oral anticoagulants (DOACs) are effective for stroke prevention in nonvalvular atrial fibrillation (AF). Cardioversion (CV) is frequently performed in patients with AF or flutter. To further explore the safety profile of DOACs in the context of CV, we sought to assess the prevalence of intracardiac thrombi under DOAC therapy in comparison with treatment with vitamin K antagonists. A total of 672 transesophageal echocardiograms performed in 643 patients with a history of nonvalvular AF were analyzed. The median CHA2DS2-VASc score was 4. Cases were stratified according to anticoagulation with dabigatran (n = 79), rivaroxaban (n = 122), phenprocoumon (n = 180), or bridging therapy (n = 287). In a subgroup analysis, only patients receiving phenprocoumon with an international normalized ratio ≥2 on the day of the investigation or on DOAC therapy for ≥3 weeks were considered. The prevalence of intracardiac thrombi under phenprocoumon was significantly higher than under DOACs (phenprocoumon, 17.8%; all DOACs, 3.9%; dabigatran, 3.8%; rivaroxaban, 4.1%) and showed no significant difference to bridging therapy (12.5%). In patients with sufficient short-term anticoagulation, similar differences between DOAC and phenprocoumon groups were observed (phenprocoumon, 18.4%; all DOACs, 3.8%; dabigatran, 0%; rivaroxaban, 6.6%). The influence of anticoagulation medication on thrombus rates was confirmed after adjusting for baseline intergroup differences regarding left atrial size and CHA2DS2-VASc score. In conclusion, the prevalence of intracardiac thrombi was lower under DOAC therapy than under phenprocoumon in this high-risk patient cohort. Safety of CV during DOAC treatment requires further prospective evaluation. Copyright © 2015 Elsevier Inc. All rights reserved.
    The American Journal of Cardiology 12/2014; 115(5). DOI:10.1016/j.amjcard.2014.12.016 · 3.43 Impact Factor

Full-text (2 Sources)

Download
5,258 Downloads
Available from
May 21, 2014